BPC-1 is under clinical development by Meabco and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect BPC-1’s likelihood of approval (LoA) and phase transition for Metastatic Breast Cancer took place on 25 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BPC-1 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

BPC-1 overview

BPC-1 is under development for the treatment of metastatic breast cancer, pancreatic cancer and Burkitt Lymphoma. The therapeutic candidate is administered intramuscularly. BP-C1 (combination of BP-Cx-1 and platinum) is a benzene-poly-carboxylic acid, cis-diammineplatinum (II) dichloride complex. It acts by targeting DNA. It was also under development for the treatment of lymphoma and other solid tumors including bladder, prostate, colon, and head & neck cancers.

Meabco overview

Meabco is a pharmaceutical company that develops drugs for cancer and radiation induced injuries. The company developed product candidates based on its patented technology that comprise BP-C1 and BP-C2 that possess immunomodulating properties. Its BP-C1 helps to treat a variety of cancers with its apoptotic and anti-proliferative properties and is used both as monotherapy and in combinations with other cancer drugs. Meabco’s BP-C2 drug candidate improves the hematopoietic system and protects the gastrointestinal system and helps in their recovery following damage induced by radiation, disease and chemical agents. The company collaborates with institutions and scientists to enhance its research and development. Meabco is headquartered in Copenhagen, Denmark.

Quick View BPC-1 LOA Data

Report Segments
  • Innovator
Drug Name
  • BPC-1
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.